Bionical Emas sells EMAS Pharma to Kester Capital following strategic review
December 09, 2024 02:00 ET
|
Bionical Emas
Bionical Emas, the Early Access Programs and Clinical Trial Supply business, is selling EMAS Pharma to Kester Capital and an incoming executive team.
Kester Capital backs experienced management team in acquiring EMAS Pharma
December 09, 2024 02:00 ET
|
EMAS Pharma
Kester Capital, alongside a new senior management team, has acquired EMAS Pharma, the clinical development division of Bionical Emas.
Microbiome Diagnostics Market Revenue Projections to 2034 by Product, Technology, Sample, Application, End-user, and by Region
December 05, 2024 11:13 ET
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Microbiome Diagnostics Market by Product, Technology, Sample, Application, End-user, and by Region" report has been added to ResearchAndMarkets.com's...
Human Microbiome Strategic Business Research Report 2024: Global Market to Reach $2.8 Billion by 2030 from $486 Million in 2023, Driven by Dow, DuPont de Nemours, and Enterome Among Others
December 03, 2024 11:13 ET
|
Research and Markets
Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "Human Microbiome - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Human Microbiome...
Derm-Biome Pharmaceuticals adds Dr. Jerry Tan, internationally renowned expert in acne and acne scarring, to its Scientific Advisory Board
November 25, 2024 10:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company developing safe and highly effective topical treatments...
Microbiome Sequencing Services Business Report 2024-2030: Strong Investment in Genomics Research Crucial for Market Growth
November 21, 2024 06:52 ET
|
Research and Markets
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Microbiome Sequencing Services - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
November 18, 2024 08:00 ET
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
November 18, 2024 03:00 ET
|
EnteroBiotix
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase...
UPDATE - Canada’s First Precision Health and Longevity Summit 2024: Uniting Global Leaders on November 15-16
November 13, 2024 16:34 ET
|
BioAro
Canada's first Precision Health and Longevity Summit 2024 gathers world leaders in Calgary to pioneer strategies in personalized health, AI, and longevity.
EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis
November 11, 2024 03:00 ET
|
EnteroBiotix
EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy...